BNP/CALL/GILEAD SCIENCES/100/0.1/19.12.25

BNP/CALL/GILEAD SCIENCES/100/0.1/19.12.25 Share Price

DE000PC2YBR6

Market Closed - Boerse Frankfurt Warrants 20:50:37 17/05/2024 BST
0.13 ^EUR	-7.14%

Current month	+8.33%
1 month	-23.53%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BNP/CALL/GILEAD SCIENCES/100/0.1/19.12.25

Latest news about GILEAD SCIENCES, INC.

Transcript : Gilead Sciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 10:30 AM	05-15
Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	05-14
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy	05-14	BU
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	05-09	BU

More news

Quotes 5-day view

Date	Price	Change
17/05/24	0.13	-7.14%
16/05/24	0.14	+7.69%
15/05/24	0.13	-7.14%
14/05/24	0.14	+7.69%
13/05/24	0.13	+8.33%

Real-time Boerse Frankfurt Warrants

Last update May 17, 2024 at 08:50 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	BNP Paribas
WKN	PC2YBR
ISIN	DE000PC2YBR6
Date issued	04/01/2024
Strike	100 $
Maturity	19/12/2025 (581 Days)
Parity	10 : 1
Emission price	0.45 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	0.78 €
Lowest since issue	0.09 €
Spread	0.02 €
Spread %	13.33%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company